Selective chemotherapeutic strategies using catalytic antibodies: A common pro-moiety for antibody-directed abzyme prodrug therapy

Journal of Immunological Methods

Volumn 269, Issue 1-2, 2002, Pages 269-281

  Kakinuma, Hiroyuki ^a   Fujii, Ikuo ^b   Nishi, Yoshisuke ^a  

^a JAPAN TOBACCO INC   (Japan)

^b Bimolecular Eng Research Institute   (Japan)

Author keywords

Antibody directed abzyme prodrug therapy; Catalytic antibody; Prodrug; Vitamin B6

Indexed keywords

ANTINEOPLASTIC AGENT; BUTYRIC ACID; CATALYTIC ANTIBODY; HYDROLASE; PHOSPHONIC ACID DERIVATIVE; PRODRUG; PYRIDOXINE; PYRIDOXINE DERIVATIVE;

ANIMAL CELL; ANIMAL MODEL; ANTIBODY DIRECTED ENZYME THERAPY; ANTIBODY PRODUCTION; ARTICLE; CANCER INHIBITION; CATALYSIS; CONTROLLED STUDY; DRUG ACTIVATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG HALF LIFE; DRUG STABILITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HELA CELL; HUMAN; HUMAN CELL; HYDROLYSIS; HYDROPHOBICITY; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TOXICITY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, CATALYTIC; ANTINEOPLASTIC AGENTS; CELL DIVISION; CHLORAMBUCIL; HAPTENS; HELA CELLS; HUMANS; HYDROLYSIS; IBUPROFEN; MICE; MICE, INBRED MRL LPR; MUSTARD PLANT; PRODRUGS; SUBSTRATE SPECIFICITY; VITAMIN B 6;

EID: 0036837182     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(02)00241-7     Document Type: Article

References (33)

1. Bagshawe K.D. Antibody directed enzymes revive anti-cancer prodrug concept. Br. J. Cancer. 56:1987;531.
2. Bagshawe K.D. Antibody-directed enzyme prodrug therapy for cancer: its theoretical basis and application. Mol. Med. Today. 1:1995;424.
3. Bagshawe K.D., Sharma S.K. Cyclosporine delays host immune response to antibody enzyme conjugate in ADEPT. Transplant. Proc. 28:1996;3156.
4. Bagshawe K.D., Sharma S.K., Burke P.J., Melton R.G., Knox R.J. Developments with targeted enzymes in cancer therapy. Curr. Opin. Immunol. 11:1999;579.
5. Bauminger S., Wilchek M. The use of carbodiimides in the preparation of immunizing conjugates. Vunakis H.V., Langone J.J. Methods in Enzymology. vol. 70:1980;151 Academic Press, New York.
6. Campbell D.A., Gong B., Kochersperger L.M., Yonkovich S.Y., Gallop M.A., Schultz P.G. Antibody-catalyzed prodrug activation. J. Am. Chem. Soc. 116:1994;2165.
7. Chen S.-T., Fang J.-M. Preparation of optically active tertiary alcohols by enzymatic methods. Application to the synthesis of drugs and natural products. J. Org. Chem. 62:1997;4349.
8. Christen P., Metzler D.E. Transaminase. 1985;Wiley, New York.
9. Flower R.J., Vane J.R. Inhibition of prostaglandin biosynthesis. Biochem. Pharmacol. 23:1974;1439.
10. Green L.L., Hardy M.C., Maynard-Currie C.E., Tsuda H., Louie D.M., Mendez M.J., Abderrahim H., Noguchi M., Smith D.H., Zeng Y., David N.E., Sasai H., Garza D., Brenner D.G., Hales J.F., McGuinness R.P., Capon D.J., Klapholz S., Jakobovits A. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat. Genet. 7:1994;13-21.
11. Hockley K., Baxter D. Use of the 3T3 cell-Neutral Red uptake assay for irritants as an alternative to the rabbit (Draize) test. Food Chem. Toxic. 24:1986;473.
12. Hovinen J. A convenient synthesis of N,N-bis(2-chloroethyl)-p-aminophenylacetic acid, a major metabolite of the cancer chemotherapeutic agent chlorambucil. Acta Chem. Scand. 50:1996;1174.
13. Huennekens F.M. Tumor targeting: activation of prodrugs by enzyme-monoclonal antibody conjugates. Trends Biotech. 12:1994;234.
14. Januszewicz E., Rabizadeh E., Novogradsky A., Shaklai M. Butyric acid: inhibition of non-leukemic and chronic myeloid leukemia granulocyte macrophage clonal growth. Med. Oncol. Tumor Pharmacother. 5:1988;259.
15. Köhler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 256:1975;495.
16. Kurosawa T., Iwasa S., Kakinuma A. Enhanced fibrinolysis by a bispecific monoclonal antibody reactive to fibrin and tissue plasminogen activator. Bio/Technology. 7:1989;1163.
17. Lavelle D., Chen Y.-H., Hankewych M., DeSimone J. Butyrate induces growth arrest and apoptosis of human myeloma cell lines independent of effects on Il-6 receptor expression. Blood. 194(Suppl. 1):1999;124a.
18. Martin J., Stribbling S.M., Poon G.K., Begent R.H.J., Napier M., Sharma S.K., Springer C.J. Antibody directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trials. Cancer Chemother. Pharmacol. 40:1997;189.
19. Miyashita H., Karaki Y., Kikuchi M., Fujii I. Prodrug activation via catalytic antibodies. Proc. Natl. Acad. Sci. U. S. A. 90:1993;5337.
20. Nickander R., McMahon F.G., Ridolfo A.S. Nonsteroidal anti-inflammatory agents. Annu. Rev. Pharmacol. Toxicol. 19:1979;469.
21. Novogradsky A., Dvir A., Ravid A., Shkolnik T., Stenzel K.H., Rubin A.L., Zaizov R. Effect of polar organic compounds on leukemic cells, butyrate-induced partial remission of acute myelogenous leukemia in a child. Cancer. 51:1983;9.
22. Nudelman A., Ruse M., Aviram A., Rabizadeh E., Shaklai M., Zimrah Y., Rephaeli A. Novel anticancer prodrugs of butyric acid: 2. J. Med. Chem. 35:1992;687.
23. Prasad K.N. Butyric acid: a small fatty acid with diverse biological functions. Life Sci. 27:1980;1351.
24. Rader C., Cheresh D.A., Barbas C.F. III A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries. Proc. Natl. Acad. Sci. U. S. A. 95:1998;8910.
25. Rephaeli A., Rabizadeh E., Nordenberg J., Kluska A., Prokocimer M., Rosenberg I., Novogradsky A., Shaklai M. Effect of the cell differentiation inducers butyrate, retinoic acid and low dose cytosine on lymphatic leukemia. Comparison of in vitro and in vivo study. Blood. 68(Suppl. 1):1986;192a.
26. Roehrig G.R., Billman J.H., Marcec J., Fritz P., Shea F. Synthesis and antitumor activity of 4-[p-[bis(2-chloroethyl)amino]phenyl]butyrates. J. Pharm. Sci. 69:1980;1232.
27. Ross W.C.J., Warwick G.P., Roberts J.J. Aryl-2-halogenoalkylamines: Part XIV. Some compounds possessing latent cytotoxic activity. J. Chem. 1955;3110.
28. Shabat D., Rader C., List B., Lerner R.A., Barbas C.F. III Multiple event activation of a generic prodrug trigger by antibody catalysis. Proc. Natl. Acad. Sci. U. S. A. 96:1999;6925.
29. Syrigos K.N., Epenetos A.A. Antibody directed enzyme prodrug therapy (ADEPT): a review of the experimental and clinical considerations. Anticancer Res. 19:1999;605.
30. Takahashi N., Kakinuma H., Hamada K., Shimazaki K., Yamasaki Y., Matsushita H., Nishi Y. Improved generation of catalytic antibodies by MRL/MPJ-lpr/lpr autoimmune mice. J. Immunol. Methods. 235:2000;113.
31. Takahashi N., Kakinuma H., Liu L., Nishi Y., Fujii I. In vitro abzyme evolution to optimize antibody recognition for catalysis. Nat. Biotechnol. 19:2001;563.
32. 6. Proc. Soc. Exp. Biol. Med. 43:1940;116.
33. Wentworth P., Datta A., Blakey D., Boyle T., Partridge L.J., Blackburn G.M. Toward antibody-directed "abzyme" prodrug therapy, ADAPT: carbamate prodrug activation by a catalytic antibody and its in vitro application to human tumor call killing. Proc. Natl. Acad. Sci. U. S. A. 93:1996;799.